Treatment of chronic cough: P2X3 receptor antagonists and beyond

Sykes, Dominic L.; Zhang, Mengru; Morice, Alyn H.

Abstract

For years chronic cough (CC) has presented an enormous physical, psychological, and social burden on those who experience it, with no approved pharmacological therapies to assuage their symptoms. With our improved understanding of the pathophysiological mechanisms of CC, primarily the recognition of neuronal dysregulation in its aetiology, there appears to be a new hope for such patients. In this review we discuss the multitude of proposed pharmacological targets in CC, including the promising results produced by the antagonism of P2X3 receptors. We also assess the evidence of other peripherally acting pharmacolgical agents still in development.

Citation

Sykes, D. L., Zhang, M., & Morice, A. H. (2022). Treatment of chronic cough: P2X3 receptor antagonists and beyond. Pharmacology and Therapeutics, 237, Article 108166. https://doi.org/10.1016/j.pharmthera.2022.108166

• Journal Article Type: Review
• Acceptance Date: Mar 6, 2022
• Online Publication Date: Mar 6, 2022
• Publication Date: 2022-09
• Deposit Date: May 10, 2022
• Journal: Pharmacology and Therapeutics
• Print ISSN: 0163-7258
• Electronic ISSN: 1879-016X
• Publisher: Elsevier
• Peer Reviewed: Peer Reviewed
• Volume: 237
• Article Number: 108166
• DOI: https://doi.org/10.1016/j.pharmthera.2022.108166
• Keywords: Cough; Gefapixant; P2X3 receptors; Purinergic receptors; ATP
• Public URL: https://hull-repository.worktribe.com/output/3951001